Mountain View

Frequence Achieves 80% Growth in Media Sales through Q3, 2021

Retrieved on: 
Wednesday, October 27, 2021
Intelligence, Advertising, Growth, Software, GLOBE, Industry, Great Places, Automation, AI, Mobile phone

MOUNTAIN VIEW, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Frequence, a leader in advertising sales automation and workflow software, achieved 80% growth in media sales the company reported today.

Key Points: 
  • MOUNTAIN VIEW, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Frequence, a leader in advertising sales automation and workflow software, achieved 80% growth in media sales the company reported today.
  • Its been an incredible year at Frequence, and I couldnt be more proud of the teams performance under very challenging circumstances, said Oliver Jacob of Frequence.
  • Frequence has also increased global headcount by 60% from last year and added several key executives in 2021.
  • Frequence is the leading provider of software for media companies to automate and grow their local advertising sales.

Win Ghoulish Prizes With Bingo Clash This Halloween

Retrieved on: 
Monday, October 25, 2021
GLOBE, PayPal, Amusement arcade, Online gambling

As fun as Halloween-themed games sound, can one truly win money with Bingo Clash?

Key Points: 
  • As fun as Halloween-themed games sound, can one truly win money with Bingo Clash?
  • Bingo Clash is a skill-based bingo game that allows players to get matched with other real players based on their skill levels.
  • Whether you're an avid bingo player who enjoys honing your skill by playing one-on-one against someone elseor you have a competitive streak wanting you to win against a large group of bingo players in tournaments, Bingo Clash has it all.
  • Players can simply participate in 1v1 or tournament games to win real cash prizes and brush up on their Bingo skills as well.

Kindred Healthcare and El Camino Health Announce Plans for Inpatient Rehabilitation Hospital

Retrieved on: 
Friday, October 22, 2021
Hospitals, Health, Practice Management, Nursing, Managed Care, Magnet, CMS, Neurology, Quality of life, Technology, LinkedIn, Spine, Hospital, Cancer, Elective surgery, Mountain View, El Camino, Twitter, Organization, Health care, Partnership, Patient, Centers for Medicare & Medicaid Services, Kindred Healthcare, Physician, Urology, Adult, LLC, Medicare, Silicon, Growth, Multimedia, Stroke, Health, Nursing, American Nurses Credentialing Center, Population, Heart, Center

Kindred Healthcare, LLC (Kindred) announced today that it has signed a definitive agreement with El Camino Health to create a joint venture to construct and operate a 52-bed inpatient rehabilitation hospital in Sunnyvale, California, a city in northwest Santa Clara County.

Key Points: 
  • Kindred Healthcare, LLC (Kindred) announced today that it has signed a definitive agreement with El Camino Health to create a joint venture to construct and operate a 52-bed inpatient rehabilitation hospital in Sunnyvale, California, a city in northwest Santa Clara County.
  • For 11 years, El Camino Health and Kindred have worked together in providing acute rehabilitation at El Camino Healths Los Gatos hospital campus to help patients recover and rejoin the community after traumatic illness or injury.
  • For more than a decade, the dedicated professionals of both El Camino and Kindred have provided outstanding rehabilitative care to El Camino Healths patients and thanks to their proven success in improving health outcomes, we are excited to expand our relationship with El Camino Health, said Russ Bailey, president, Kindred Rehabilitation Services.
  • Kindred Healthcare, LLC is the nations leading specialty hospital company delivering acute health services in its long-term acute care hospitals, inpatient rehabilitation hospitals, acute rehabilitation units, and behavioral health line of business, all specializing in treating the most medically complex patients.

BigPanda and Blackrock 3 Partners Announce the Winners of the 2021 Incident Commander Awards

Retrieved on: 
Thursday, October 21, 2021
Knowledge, Autonomous peripheral operation, BigPanda, Efficiency, SAN, Artificial Intelligence for IT Operations, PlayStation, Sequoia Capital, Intel, Industry, GlobalGiving, ITIL, SRE, Partner, Transmission service request, Black Rock, Insight Partners, Cisco Systems, Noise, DevOps, Leadership, Time, Future, Tom Clancy's Op-Center, Hospital incident command system (US), San Francisco Bay Area, Battery Ventures, GameStop, Citrix Systems, Automation, GLOBE, Vrio Corp., Management, Online shopping

SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- BigPanda, Inc., provider of the first Event Correlation and Automation platform powered by AIOps, and online incident management academy Blackrock 3 Partners, today announced the winners of the 2021 Incident Commander, a peer-voted award program.

Key Points: 
  • SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- BigPanda, Inc., provider of the first Event Correlation and Automation platform powered by AIOps, and online incident management academy Blackrock 3 Partners, today announced the winners of the 2021 Incident Commander, a peer-voted award program.
  • The winners of this years Incident Commander Awards have demonstrated exceptional leadership and talent, resolving outages and other IT issues around the clock under high-stakes circumstances.
  • BigPanda and Blackrock 3 Partners developed the Incident Commander award program to specifically acknowledge individuals who rise above the alerts and outages to perform their jobs like true Incident Commanders.
  • BigPanda is backed by top-tier investors including Sequoia Capital, Mayfield, Battery Ventures, Greenfield Partners and Insight Partners.

NeuroPace to Report Third Quarter 2021 Financial Results on November 10, 2021

Retrieved on: 
Wednesday, October 20, 2021
Responsive neurostimulation device, Patient, Epilepsy, Population, Anticonvulsant, Lists of diseases, GLOBE, Webcast, Seizure, Pharmaceutical industry

MOUNTAIN VIEW, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the third quarter of 2021 after market close on Wednesday, November 10, 2021.

Key Points: 
  • MOUNTAIN VIEW, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the third quarter of 2021 after market close on Wednesday, November 10, 2021.
  • The companys management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time.
  • Live audio of the webcast will be available on the Investors section of the companys website at: https://investors.neuropace.com.
  • The webcast will be archived and available for replay for at least 90 days after the event.

Axalbion Announces First Patients Treated in Phase 2 Clinical Trial in Chronic Cough with AX-8, a Novel TRPM8 Agonist

Retrieved on: 
Wednesday, October 20, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Nobel Prize, Mountain View, MD, Nobel Prize in Physiology or Medicine, CA, Chronic cough, EudraCT, Patient, ODT, Chronic obstructive pulmonary disease, Doctor of Philosophy, Skin, Disease, Peripheral neuropathy, Duane syndrome, TRPM8, Research, Cough, University, Medicine, Inflammation, GERD, Asthma, Tongue, Safety, Trial of the century, Pharmaceutical industry, Poultry, AX-8 and TRPM8, Chronic Cough, Axalbion, AX-8 AND TRPM8, CHRONIC COUGH, AXALBION

AX-8 has a novel mechanism of action targeting the TRPM8 ion channel, which may help normalize upper airway sensitivity in chronic cough patients, distinguishing it from other strategies in development.

Key Points: 
  • AX-8 has a novel mechanism of action targeting the TRPM8 ion channel, which may help normalize upper airway sensitivity in chronic cough patients, distinguishing it from other strategies in development.
  • With its safety profile and ease of administration, AX-8 has the potential to be a first-in-class drug to treat chronic cough.
  • The Phase 2 trial is a randomized, double-blind, placebo-controlled, crossover study evaluating the efficacy and safety of AX-8 in approximately 50 patients with refractory or unexplained chronic cough.
  • Axalbion is a privately held, clinical-stage biotechnology company developing novel medicines for the millions of patients who suffer from chronic respiratory disorders such as chronic cough.

NeuroPace Announces Addition of Lisa Andrade to the Board

Retrieved on: 
Tuesday, October 19, 2021
Software, Business, Seizure, EEG, Biomedical engineering, Duke University, Lists of diseases, Technology, Board of directors, University, Abbott, MBA, Responsive neurostimulation device, Epilepsy, Board, Research, FDA, Quality of life, Insurance, IPO, Wharton School of the University of Pennsylvania, GLOBE, Brain, Patient, Engineering, St. Jude Medical, Health, Physician, Cognition, Marketing, System, Management, Pharmaceutical industry

MOUNTAIN VIEW, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. , (Nasdaq:NPCE) a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced the addition of Lisa Andrade to its Board of Directors.

Key Points: 
  • MOUNTAIN VIEW, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. , (Nasdaq:NPCE) a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced the addition of Lisa Andrade to its Board of Directors.
  • Lisa Andrade joins NeuroPace with over 25 years of experience in both large and early-stage medtech, software and technology companies.
  • Currently, Ms. Andrade is CEO of M33, an executive coaching and leadership development firm, which she founded in 2018.
  • "I would also like to thank Evan Norton for his service as a board member of NeuroPace.

BigPanda’s Pandapalooza Customer Festival to Take Place Nov. 2-3

Retrieved on: 
Thursday, October 14, 2021
MTV, NOC, Sequoia, Technology, Autonomous peripheral operation, BigPanda, Fortune 500, Intel, Artificial Intelligence for IT Operations, Automation, Cisco Systems, Triage, Music, Marketing, Movement, DevOps, GLOBE, Radio, Insight Partners, SAN, RCA, Nightclub, Risk management

SAN FRANCISCO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- BigPanda, Inc., the leader in Event Correlation and Automation powered by AIOps, today announced its plans for Pandapalooza 21, its annual customer festival.

Key Points: 
  • SAN FRANCISCO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- BigPanda, Inc., the leader in Event Correlation and Automation powered by AIOps, today announced its plans for Pandapalooza 21, its annual customer festival.
  • This years event will take place online on Nov. 2 and 3, with engaging content presented in the style of the early days of MTV in the wake of the networks 40th anniversary.
  • We are thrilled to bring them together in a festival-like forum and talk about what comes next...for them and us!
  • With BigPanda, businesses prevent IT outages, improve incident management and deliver incredible customer experiences.

WSO2 Introduces Asgardeo Next-Generation IDaaS to Cut the Complexity Out of Managing User Access to Client-Facing Applications

Retrieved on: 
Wednesday, October 13, 2021
MFA, Identity management, Organization, SAML, Access management, Freedom, OpenID, Time, Environment, LinkedIn, IDE, App Store (iOS/iPadOS), URL, ID, CAS, Knowledge, Security Assertion Markup Language, API, WS-Federation, Traction, SDK, WSO2, CIAM, Forrester Research, GLOBE, Bridge, University, Central Authentication Service, Software as a service, SSO, As a service, Twitter, CA, Forrester, CTO, Online shopping, Video game console, Sales, Cryptocurrency

WSO2 addresses this challenge with todays introduction of its next-generation identity as a service (IDaaS) solution, Asgardeo.

Key Points: 
  • WSO2 addresses this challenge with todays introduction of its next-generation identity as a service (IDaaS) solution, Asgardeo.
  • The IDaaS provides built-in CIAM best practices and workflows via a range of templates and other no code/low code options.
  • As a result, development teams using Asgardeo can:
    Quickly deliver safe, secure and robust cloud native digital applications that give customers confidence their data will be protected.
  • Streamline security reviews and approvals by codifying policies and standards, freeing developers to concentrate on building out their core applications.

IGM Biosciences Announces Leadership Appointments and Formation of IGM Infectious Diseases and IGM Autoimmunity and Inflammation Business Units

Retrieved on: 
Monday, October 11, 2021

MOUNTAIN VIEW, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the formation of two business units: IGM Infectious Diseases and IGM Autoimmunity and Inflammation. These new business units will utilize and build upon IGM’s platform technology to create and develop novel IgM and IgA antibodies to address infectious diseases, autoimmunity and inflammation. Both business units will be headquartered in the greater Philadelphia area of Pennsylvania.

Key Points: 
  • John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious Diseases
    MOUNTAIN VIEW, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the formation of two business units: IGM Infectious Diseases and IGM Autoimmunity and Inflammation.
  • These new business units will utilize and build upon IGMs platform technology to create and develop novel IgM and IgA antibodies to address infectious diseases, autoimmunity and inflammation.
  • To lead the IGM Autoimmunity and Inflammation business unit, IGM today announced the appointment of Mary Beth Harler, M.D., as President.
  • Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies.